Endocarditis Clinical Trials

Find Endocarditis Clinical Trials Near You

Impact on Mortality of the Choice Between a Mono- Versus Combination Antibiotic Therapy in Enterococcus Faecalis Bacteremia

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Enterococcus faecalis is a germ frequently responsible for bacteremia which can be severe with 15-25% risk of mortality and 26% risk of infectious endocarditis. There is no recommendation for the treatment of simple Enterococcus faecalis bacteremia (meaning without infectious endocarditis at diagnosis), nor studies comparing monotherapy versus combination antibiotic therapy. Our main objective is to study the impact on mortality of bacteriostatic monotherapy and bactericidal combination antibiotic therapy in patients with Enterococcus faecalis bacteremia. We aim to also study the mortality up to three months, the failures of treatment, the modalities of treatment, the renal toxicity and the bacterial resistance.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:

• Subject of legal age (≥18 years)

• Having a positive blood culture result for Enterococcus faecalis identified within the microbiology laboratory of the University Hospital of Strasbourg during the period from 01 January 2017 to 31 December 2023.

Locations
Other Locations
France
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
RECRUITING
Strasbourg
Contact Information
Primary
Yvon RUCH, MD
yvon.ruch@chru-strasbourg.fr
33 3 69 55 12 1
Time Frame
Start Date: 2024-02-24
Estimated Completion Date: 2025-12
Participants
Target number of participants: 700
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Strasbourg, France

This content was sourced from clinicaltrials.gov